Tenax Therapeutics Reports 189% Increase in Operating Expenses and $52.6 Million Net Loss for 2025

Tenax Therapeutics, Inc. reported significant financial developments in its recent 10-K filing for the fiscal year ending December 31, 2025. The company, which focuses on developing cardiopulmonary therapies, recorded total operating expenses of $56.4 million, a substantial increase of 189% from $19.5 million in the previous year. This rise was primarily driven by a 157% increase in research and development expenses, which reached $32.7 million, largely due to costs associated with ongoing Phase 3 clinical trials for its lead product candidate, levosimendan. General and administrative expenses also surged by 249% to $23.7 million, reflecting increased operational costs as the company expanded its workforce and clinical activities.

In terms of revenue, Tenax reported a net loss of $52.6 million for 2025, compared to a net loss of $17.6 million in 2024, marking a 199% increase in losses. The company attributed this increase to higher operational costs associated with its clinical trials and the expansion of its employee base. Despite these losses, Tenax's interest income doubled to $3.8 million, up from $1.9 million in the prior year, as a result of increased cash reserves and higher interest rates.

Strategically, Tenax has made significant progress in its clinical development pipeline. The company successfully completed its target enrollment of 230 patients for the LEVEL trial in March 2026 and initiated the LEVEL-2 trial in December 2025. These trials are critical for evaluating the efficacy of oral levosimendan in treating pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF). The company plans to submit marketing authorization applications following the completion of these trials.

Operationally, Tenax has focused on expanding its clinical trial capabilities and enhancing its intellectual property portfolio. As of December 31, 2025, the company had cash and cash equivalents of $97.6 million, bolstered by a private placement financing that raised approximately $25 million in March 2025. This funding is expected to support ongoing clinical trials and operational needs through at least the end of 2027. The company has also indicated that it will require additional capital to continue its development efforts, particularly for levosimendan and potentially for imatinib, which remains part of its product pipeline.

Looking ahead, Tenax remains optimistic about its prospects, emphasizing the potential of its product candidates to address significant unmet medical needs in the cardiopulmonary space. The company is committed to advancing its clinical trials and is actively seeking additional funding opportunities to support its growth and development initiatives.